Approval (2017) FDA News Release (March 8th, 2024): FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight FDA News Release (August 15th, 2025): FDA Approves Treatment for Serious Liver Disease Known as MASH OZEMPIC (semaglutide) injection, for subcutaneous use
The side effect profiles of these two compounds are dramatically different, and for some people, that difference tips the scale
However, its important to know that compounded tirzepatide and semaglutide are not FDA-approved
Similarly, these medications slow gastric emptying, which can sometimes lead to nausea or a lack of appetite
Needle reuse can cause dulling and barb formation, significantly increasing injection pain
Glucagonlike peptide1 receptor agonists for major neurocognitive disorders